Trial intelligence / Profile preview

NoVa

NCT06464510Phase 3Recruiting

Sponsor
HCor
Start
Nov 2024
Primary completion
Aug 2027
Modality
Peptides
Countries
1
01

Overview

A Phase 3 trial of vasopressin in septic shock, sponsored by HCor. Started Nov 2024; status: recruiting.

02

Drugs

vasopressin
03

Conditions

septic shock

Beyond the preview

Go deeper on NCT06464510.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT06464510.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call